All BioSpace - All News BioSpace - Business BioSpace - Drug Development BioSpace - FDA BioSpace - Deals BioSpace - Policy BioSpace - Drug Delivery FiercePharma - Main FiercePharma - Manufacturing FiercePharma - Marketing FiercePharma - Vaccines BioPharma Dive FierceBiotech - Main FierceBiotech - Biotech FierceBiotech - Medtech FierceBiotech - CRO BioSpace - Drug Development Otsuka energizes IgA neuropathy space with new Phase 3 Voyxact data By inhibiting the APRIL cascade, Otsuka Pharmaceuticals’ Voyxact slowed kidney function decline in patients with IgAN, opening up a potential path for full approval while also reading through to Vertex... June 5, 2026 BioSpace - All News Stakeholders want Makary’s voucher program paused, calls for FDA independence The FDA hasn’t been transparent and open enough with how it has implemented the Commissioner’s National Priority Voucher program, patient, industry and trade groups said Thursday. June 5, 2026 BioSpace - FDA Stakeholders want Makary’s voucher program paused, call for FDA independence The FDA hasn’t been transparent and open enough with how it has implemented the Commissioner’s National Priority Voucher program, patient, industry and trade groups said Thursday. June 5, 2026 BioPharma Dive Pharma is betting big on PD-1/VEGF bispecifics. But are companies chasing the wrong target? While many drugmakers are focused on lung cancer, evidence shows the liver may be a better bet. June 5, 2026 BioSpace - All News Surviving (and thriving with) DEI in biotech Rather than getting hung up on what to call DEI in the workplace, leaders should take three specific actions to help their employees embrace and engage with it. Companies and... June 5, 2026 FierceBiotech - Main At first public hearing for FDA’s CNPV program, industry support meets ‘deep concern’ from experts On Thursday, the public had the first chance to air their grievances about the FDA’s controversial Commissioner’s National Priority Voucher (CNPV) pilot program, the flagship initiative of recently departed agency... June 4, 2026 FierceBiotech - Biotech At first public hearing for FDA’s CNPV program, industry support meets ‘deep concern’ from experts On Thursday, the public had the first chance to air their grievances about the FDA’s controversial Commissioner’s National Priority Voucher (CNPV) pilot program, the flagship initiative of recently departed agency... June 4, 2026 BioSpace - All News Massachusetts’ life sciences employment dipped last year following 14 years of growth: report Massachusetts’ life sciences jobs declined 1% in 2025, according to a new MassBioEd report. However, the report is projecting industry employment will increase 9.7% by 2030. It also noted reskilling... June 4, 2026 FiercePharma - Main It's unanimous: SCOTUS agrees with Hikma in 'skinny label' case vs. Amarin With a resounding unanimous vote, the U.S. Supreme Court has sided with Hikma Pharmaceuticals, ruling that its generic version of Amarin’s fish oil-derived cardiovascular drug Vascepa does not infringe patents... June 4, 2026 BioPharma Dive Alnylam, Inceptive ink AI deal potentially worth $2B The RNA-focused drugmaker says Inceptive's tools will help prioritize the best development options as well as speed up the research process. June 4, 2026 BioSpace - All News Lilly and Boehringer roll back billions in German investments over health budget cuts With Germany moving to curb healthcare spending, Eli Lilly and Boehringer Ingelheim have rethought plans to invest in facilities, including a manufacturing plant for GLP-1 drugs. June 4, 2026 BioSpace - Business Lilly and Boehringer roll back billions in German investments over health budget cuts With Germany moving to curb healthcare spending, Eli Lilly and Boehringer Ingelheim have rethought plans to invest in facilities, including a manufacturing plant for GLP-1 drugs. June 4, 2026 BioSpace - Drug Delivery Lilly and Boehringer roll back billions in German investments over health budget cuts With Germany moving to curb healthcare spending, Eli Lilly and Boehringer Ingelheim have rethought plans to invest in facilities, including a manufacturing plant for GLP-1 drugs. June 4, 2026 BioSpace - All News Peptide biotech Parabilis targets up to $476M IPO Parabilis Medicines is joining the parade of biotechs going public, sharing plans to raise as much as $476.4 million to help advance its lead cancer candidate into late-stage testing. June 4, 2026 BioSpace - Business Peptide biotech Parabilis targets up to $476M IPO Parabilis Medicines is joining the parade of biotechs going public, sharing plans to raise as much as $476.4 million to help advance its lead cancer candidate into late-stage testing. June 4, 2026 BioSpace - Deals Peptide biotech Parabilis targets up to $476M IPO Parabilis Medicines is joining the parade of biotechs going public, sharing plans to raise as much as $476.4 million to help advance its lead cancer candidate into late-stage testing. June 4, 2026 BioPharma Dive An ADC specialist sinks on safety concerns for blood cancer drug Shares for ADC Therapeutics fell more than 50% after a Phase 3 trial observed a death rate that at least one analyst believes “may be difficult to accept for physicians,... June 4, 2026 BioSpace - All News ADC Therapeutics nosedives on 27 deaths in confirmatory trial for lymphoma drug In addition to a high rate of deaths, ADC Therapeutics’ Zynlonta plus rituximab showed no overall survival benefit in patients with diffuse large B cell lymphoma, casting doubt on its... June 4, 2026 BioSpace - Drug Development ADC Therapeutics nosedives on 27 deaths in confirmatory trial for lymphoma drug In addition to a high rate of deaths, ADC Therapeutics’ Zynlonta plus rituximab showed no overall survival benefit in patients with diffuse large B cell lymphoma, casting doubt on its... June 4, 2026 FiercePharma - Main ADC Therapeutics' shares plummet after patient deaths in trial of Zynlonta Three times as many deaths in the study arm versus the control arm in a trial of ADC Therapeutics' Zynlonta have raised questions about the antibody-drug conjugate (ADC), which has... June 4, 2026 BioSpace - All News Regeneron deepens relationship with CytomX, adding up to $2B and eight targets All told, CytomX Therapeutics now stands to receive up to $4 billion over the course of its partnership with Regeneron, if all milestones are met. June 4, 2026 BioSpace - Deals Regeneron deepens relationship with CytomX, adding up to $2B and eight targets All told, CytomX Therapeutics now stands to receive up to $4 billion over the course of its partnership with Regeneron, if all milestones are met. June 4, 2026 FierceBiotech - Main Autobahn races toward pivotal trial after thyroid hormone mimic eases bipolar depression in ph. 2 A stimulator of thyroid hormone receptors in the brain has successfully reduced depression severity in patients with bipolar disorder, positioning its maker Autobahn Therapeutics to speed ahead to late-stage testing. June 4, 2026 FierceBiotech - Biotech Autobahn races toward pivotal trial after thyroid hormone mimic eases bipolar depression in ph. 2 A stimulator of thyroid hormone receptors in the brain has successfully reduced depression severity in patients with bipolar disorder, positioning its maker Autobahn Therapeutics to speed ahead to late-stage testing. June 4, 2026 BioSpace - All News Alnylam hops on AI train with up to $2B Inceptive partnership Alnylam Pharmaceuticals will leverage Inceptive Nucleics’ generative machine learning models to accelerate the development of RNA interference therapies. June 4, 2026 BioSpace - Business Alnylam hops on AI train with up to $2B Inceptive partnership Alnylam Pharmaceuticals will leverage Inceptive Nucleics’ generative machine learning models to accelerate the development of RNA interference therapies. June 4, 2026 BioSpace - Deals Alnylam hops on AI train with up to $2B Inceptive partnership Alnylam Pharmaceuticals will leverage Inceptive Nucleics’ generative machine learning models to accelerate the development of RNA interference therapies. June 4, 2026 FiercePharma - Main As China biotech crackdown calls reverberate in Washington, the pushback gets louder, too Two federal lawmakers have introduced a bill seeking to apply the review requirements of the Comprehensive Outbound Investment National Security (COINS) Act to investments in Chinese biotechnology. June 4, 2026 FierceBiotech - Main As China biotech crackdown calls reverberate in Washington, the pushback gets louder, too Two federal lawmakers have introduced a bill seeking to apply the review requirements of the Comprehensive Outbound Investment National Security (COINS) Act to investments in Chinese biotechnology. June 4, 2026 FierceBiotech - Biotech As China biotech crackdown calls reverberate in Washington, the pushback gets louder, too Two federal lawmakers have introduced a bill seeking to apply the review requirements of the Comprehensive Outbound Investment National Security (COINS) Act to investments in Chinese biotechnology. June 4, 2026 FierceBiotech - Main Parabilis preps $413M IPO to fuel desmoid tumor drug into phase 3 Parabilis Medicines is gearing up for an IPO that could eventually bring in as much as $476 million to fund the phase 3 development of its desmoid tumor prospect. June 4, 2026 FierceBiotech - Biotech Parabilis preps $413M IPO to fuel desmoid tumor drug into phase 3 Parabilis Medicines is gearing up for an IPO that could eventually bring in as much as $476 million to fund the phase 3 development of its desmoid tumor prospect. June 4, 2026 FiercePharma - Main Axsome fends off generic competition to narcolepsy med Sunosi until 2040 The company inked another settlement with a prospective generic maker, leaving no further pending patent litigation for its Sunosi on the table. June 4, 2026 BioSpace - All News Rethinking hair loss treatment In this episode of Denatured, you'll be hearing from Daniel Gil, CEO of Pelage Pharmaceuticals and Francisco Ramírez-Valle, senior vice president of immunology discovery at Eli Lilly. We dive into... June 4, 2026 BioSpace - Business Rethinking hair loss treatment In this episode of Denatured, you'll be hearing from Daniel Gil, CEO of Pelage Pharmaceuticals and Francisco Ramírez-Valle, senior vice president of immunology discovery at Eli Lilly. We dive into... June 4, 2026 BioSpace - Drug Development Rethinking hair loss treatment In this episode of Denatured, you'll be hearing from Daniel Gil, CEO of Pelage Pharmaceuticals and Francisco Ramírez-Valle, senior vice president of immunology discovery at Eli Lilly. We dive into... June 4, 2026 FierceBiotech - Main Innovent, fresh from $1.2B deal, posts phase 3 win for Takeda-partnered ADC Innovent Biologics has reported a phase 3 victory for IBI343, boosting the prospects of an antibody-drug conjugate (ADC) that Takeda bet big on last year. June 4, 2026 FierceBiotech - Biotech Innovent, fresh from $1.2B deal, posts phase 3 win for Takeda-partnered ADC Innovent Biologics has reported a phase 3 victory for IBI343, boosting the prospects of an antibody-drug conjugate (ADC) that Takeda bet big on last year. June 4, 2026 FiercePharma - Main Medline earns FDA warning letter ire for repeated toxic bacteria problems Medical device distribution giant Medline has been slammed for a second time since April by an FDA warning letter that has chided the company for repeated problems centered on the... June 4, 2026 FiercePharma - Manufacturing Medline earns FDA warning letter ire for repeated toxic bacteria problems Medical device distribution giant Medline has been slammed for a second time since April by an FDA warning letter that has chided the company for repeated problems centered on the... June 4, 2026 FierceBiotech - Main Medline earns FDA warning letter ire for repeated toxic bacteria problems Medical device distribution giant Medline has been slammed for a second time since April by an FDA warning letter that has chided the company for repeated problems centered on the... June 4, 2026 BioSpace - All News The top 12 companies hiring in biopharma now Looking for a biopharma job? Check out the BioSpace list of 12 top companies hiring life sciences professionals like you. June 4, 2026 BioSpace - All News How long is too long? Weighing and accounting for employment gaps It’s not unusual for it to take unemployed biopharma professionals awhile to land new jobs. Three experts discuss when employment gaps are an issue and how to explain them to... June 4, 2026 BioPharma Dive A Spanish biotech banks $87M to make differentiated ADCs Ona Therapeutics, a Barcelona-based drugmaker, is developing next-generation drugs it says could help patients with advanced forms of breast and colorectal cancers. June 4, 2026 FierceBiotech - Main From business strategy to CAR-T responses, for Cabaletta it’s all about ‘durability’ Fierce sat down with Cabaletta's executives at EULAR to discuss their approval timeline and which areas of development they feel like they have a head start. June 4, 2026 FierceBiotech - Biotech From business strategy to CAR-T responses, for Cabaletta it’s all about ‘durability’ Fierce sat down with Cabaletta's executives at EULAR to discuss their approval timeline and which areas of development they feel like they have a head start. June 4, 2026 FierceBiotech - Main Alnylam pens $2B deal with Inceptive to transform siRNA design with AI pioneer Alnylam has partnered with the person who helped put the “T” in ChatGPT, paying $30 million to work with Jakob Uszkoreit’s Inceptive Nucleics on artificial intelligence-enabled drug design. June 4, 2026 FierceBiotech - Biotech Alnylam pens $2B deal with Inceptive to transform siRNA design with AI pioneer Alnylam has partnered with the person who helped put the “T” in ChatGPT, paying $30 million to work with Jakob Uszkoreit’s Inceptive Nucleics on artificial intelligence-enabled drug design. June 4, 2026 BioSpace - All News FDA hits Medline with warning letter over long-running contamination problem FDA inspectors found that Medline, which raised billions of dollars last year, failed to prevent repeat bacterial contamination of finished drug products. June 3, 2026 BioSpace - Business FDA hits Medline with warning letter over long-running contamination problem FDA inspectors found that Medline, which raised billions of dollars last year, failed to prevent repeat bacterial contamination of finished drug products. June 3, 2026 BioSpace - FDA FDA hits Medline with warning letter over long-running contamination problem FDA inspectors found that Medline, which raised billions of dollars last year, failed to prevent repeat bacterial contamination of finished drug products. June 3, 2026 BioPharma Dive Legend surges on early data for ‘in vivo’ lymphoma cell therapy Initial findings show that the therapy reduced or eliminated disease signs in all recipients, sparking hopes that the treatment might be competitive with “ex vivo” medicines like Novartis’ Kymriah. June 3, 2026 BioPharma Dive House bill aims to crack down on China biotech deals A proposal to add biotechnology to the COINS Act follows two big deals involving Pfizer and Bristol Myers, and comes amid U.S. fears that China’s drugmaking progress may threaten national... June 3, 2026 BioPharma Dive NewLimit’s $435M megaround; Lilly’s busy dealmaking week The anti-aging biotech has secured one of the year’s biggest venture fundings to bring its first drug into testing. Elsewhere, Lilly nabbed a “GLP-2” obesity drug and Praxis shares tumbled. June 3, 2026 BioSpace - All News ASCO’s biggest winners showcased a new era of cancer innovation Revolution Medicines stole the show at the 2026 American Society of Clinical Oncology meeting as full data from its pancreatic cancer drug lived up to expectations, while Summit and Akeso... June 3, 2026 BioSpace - Drug Development ASCO’s biggest winners showcased a new era of cancer innovation Revolution Medicines stole the show at the 2026 American Society of Clinical Oncology meeting as full data from its pancreatic cancer drug lived up to expectations, while Summit and Akeso... June 3, 2026 FiercePharma - Main Lilly, Boehringer to slash at least $1B each from planned investments in Germany In response to a planned healthcare reform initiative in Germany that would reduce the prices of branded drugs, Eli Lilly and Boehringer Ingelheim have slashed their planned investments in the... June 3, 2026 FierceBiotech - Main Lilly, Boehringer to slash at least $1B each from planned investments in Germany In response to a planned healthcare reform initiative in Germany that would reduce the prices of branded drugs, Eli Lilly and Boehringer Ingelheim have slashed their planned investments in the... June 3, 2026 BioSpace - All News NewLimit snags $435M after seeing age reversal in human liver cells NewLimit is pressing the gas, speeding into clinical trials much sooner than expected after lab research showed its epigenetic reprogramming asset reversed aging in human liver cells. June 3, 2026 BioSpace - Business NewLimit snags $435M after seeing age reversal in human liver cells NewLimit is pressing the gas, speeding into clinical trials much sooner than expected after lab research showed its epigenetic reprogramming asset reversed aging in human liver cells. June 3, 2026 BioSpace - Drug Development NewLimit snags $435M after seeing age reversal in human liver cells NewLimit is pressing the gas, speeding into clinical trials much sooner than expected after lab research showed its epigenetic reprogramming asset reversed aging in human liver cells. June 3, 2026 BioSpace - Deals NewLimit snags $435M after seeing age reversal in human liver cells NewLimit is pressing the gas, speeding into clinical trials much sooner than expected after lab research showed its epigenetic reprogramming asset reversed aging in human liver cells. June 3, 2026 BioSpace - All News Celcuity slides even after ‘practice-changing’ late-stage breast cancer data Celcuity’s gedatolisib doubled progression-free survival versus standard of care in certain patients with advanced breast cancer. Still, the biotech’s stock dropped more than 25% Tuesday. June 3, 2026 BioSpace - Drug Development Celcuity slides even after ‘practice-changing’ late-stage breast cancer data Celcuity’s gedatolisib doubled progression-free survival versus standard of care in certain patients with advanced breast cancer. Still, the biotech’s stock dropped more than 25% Tuesday. June 3, 2026 BioSpace - All News Travere beefs up rare kidney disease portfolio with up to $1.1B China deal Travere Therapeutics will gain an exclusive license to the oral BTK inhibitor civorebrutinib, which analysts at Guggenheim Securities said could be “complementary” to the biotech’s IgA nephropathy drug Filspari. June 3, 2026 BioSpace - Deals Travere beefs up rare kidney disease portfolio with up to $1.1B China deal Travere Therapeutics will gain an exclusive license to the oral BTK inhibitor civorebrutinib, which analysts at Guggenheim Securities said could be “complementary” to the biotech’s IgA nephropathy drug Filspari. June 3, 2026 BioSpace - All News FDA taps prior knowledge to expedite cell and gene therapy development A year of significant policy change at the FDA brought momentum and scrutiny into the new year. As 2026 gets underway, biopharma companies are responding to sweeping vaccine changes while... June 3, 2026 BioSpace - FDA FDA taps prior knowledge to expedite cell and gene therapy development A year of significant policy change at the FDA brought momentum and scrutiny into the new year. As 2026 gets underway, biopharma companies are responding to sweeping vaccine changes while... June 3, 2026 BioSpace - Policy FDA taps prior knowledge to expedite cell and gene therapy development A year of significant policy change at the FDA brought momentum and scrutiny into the new year. As 2026 gets underway, biopharma companies are responding to sweeping vaccine changes while... June 3, 2026 BioSpace - All News Legend soars on ‘best-in-class,’ ‘best-in-disease’ in vivo CAR T in early lymphoma study All six non-Hodgkin lymphoma patients on Legend Biotech’s CAR T therapy responded to treatment—findings that could make the biotech an attractive takeover target, according to analysts at Oppenheimer. June 3, 2026 BioSpace - Drug Development Legend soars on ‘best-in-class,’ ‘best-in-disease’ in vivo CAR T in early lymphoma study All six non-Hodgkin lymphoma patients on Legend Biotech’s CAR T therapy responded to treatment—findings that could make the biotech an attractive takeover target, according to analysts at Oppenheimer. June 3, 2026 BioSpace - All News Lilly targets kidney disease with Ascidian’s RNA exon editors for up to $1.9B For an investment of up to $1.9 billion, Eli Lilly will be able to use Ascidian Therapeutics’ platform that removes mutated exons from mRNA molecules, avoiding the expression of disease-causing... June 3, 2026 BioSpace - Deals Lilly targets kidney disease with Ascidian’s RNA exon editors for up to $1.9B For an investment of up to $1.9 billion, Eli Lilly will be able to use Ascidian Therapeutics’ platform that removes mutated exons from mRNA molecules, avoiding the expression of disease-causing... June 3, 2026 BioPharma Dive Lilly, Ascidian link up in RNA exon editing pact Worth as much as $1.9 billion, the deal directs Ascidian to help Lilly find potential drugs for genetically driven kidney diseases. June 3, 2026 FiercePharma - Main Amid Miplyffa launch, Zevra CEO aims to foster EU-style Niemann-Pick market in US As its ultra-rare disease med Miplyffa strengthens its foothold in the U.S., Zevra Therapeutics’ CEO believes the launch has the potential to convert the American treatment landscape for Niemann-Pick disease... June 3, 2026 BioSpace - All News ASCO wins from RevMed, Akeso/Summit, more; plus more Lilly and more China; ADA on deck Improved survival on display at the American Society of Clinical Oncology (ASCO) in Chicago; Pfizer’s unusual pact with China’s Innovent highlights a new type of collaboration; Eli Lilly continues its... June 3, 2026 BioSpace - Business ASCO wins from RevMed, Akeso/Summit, more; plus more Lilly and more China; ADA on deck Improved survival on display at the American Society of Clinical Oncology (ASCO) in Chicago; Pfizer’s unusual pact with China’s Innovent highlights a new type of collaboration; Eli Lilly continues its... June 3, 2026 BioSpace - Drug Development ASCO wins from RevMed, Akeso/Summit, more; plus more Lilly and more China; ADA on deck Improved survival on display at the American Society of Clinical Oncology (ASCO) in Chicago; Pfizer’s unusual pact with China’s Innovent highlights a new type of collaboration; Eli Lilly continues its... June 3, 2026 BioSpace - Deals ASCO wins from RevMed, Akeso/Summit, more; plus more Lilly and more China; ADA on deck Improved survival on display at the American Society of Clinical Oncology (ASCO) in Chicago; Pfizer’s unusual pact with China’s Innovent highlights a new type of collaboration; Eli Lilly continues its... June 3, 2026 FierceBiotech - Main Unlocking Unstructured Data with AI for Optimized Protocol Development In this podcast, Mike Eckrote, SVP, Strategic Solutions at Advarra, talks about how artificial intelligence is being used to pull insights out of structured and unstructured data sources to help... June 3, 2026 FiercePharma - Main With Cencora pact, Gilead looks to grow CAR-T treatment center network Cencora and Gilead have expanded their longstanding partnership, cutting a deal in which the distribution giant will support access to the CAR-T cancer therapies Yescarta and Tecartus. June 3, 2026 FierceBiotech - Main Regeneron pays $37M, adds $2B in biobucks to expand CytomX pact Regeneron has expanded its research alliance with CytomX Therapeutics, paying $37 million to work on conditionally active bispecifics against two targets and secure options on more programs. The expansion swells... June 3, 2026 FierceBiotech - Biotech Regeneron pays $37M, adds $2B in biobucks to expand CytomX pact Regeneron has expanded its research alliance with CytomX Therapeutics, paying $37 million to work on conditionally active bispecifics against two targets and secure options on more programs. The expansion swells... June 3, 2026 FiercePharma - Main Coffee, racetracks, beaches and more coffee—inside the ASCO 2026 exhibit floor There were 487 booths at the American Society of Clinical Oncology (ASCO)’s 2026 annual meeting in Chicago’s McCormick Place. Fierce Pharma Marketing attempted to see them all. June 3, 2026 FiercePharma - Marketing Coffee, racetracks, beaches and more coffee—inside the ASCO 2026 exhibit floor There were 487 booths at the American Society of Clinical Oncology (ASCO)’s 2026 annual meeting in Chicago’s McCormick Place. Fierce Pharma Marketing attempted to see them all. June 3, 2026 FiercePharma - Main A patient-first shift in disease language and communication The words used to describe disease can shape how patients are diagnosed, treated and understood. From mpox to obesity to the Fitzpatrick scale, outdated or imprecise language can deepen stigma... June 3, 2026 FiercePharma - Marketing A patient-first shift in disease language and communication The words used to describe disease can shape how patients are diagnosed, treated and understood. From mpox to obesity to the Fitzpatrick scale, outdated or imprecise language can deepen stigma... June 3, 2026 FiercePharma - Main FDA issues untitled letter after finding ‘eye-catching graphics’ in promotional emails The FDA has hit QOL Medical with an untitled letter over emails about Sucraid, accusing the company of creating a misleading impression about the indication for the rare disease drug. June 3, 2026 FiercePharma - Marketing FDA issues untitled letter after finding ‘eye-catching graphics’ in promotional emails The FDA has hit QOL Medical with an untitled letter over emails about Sucraid, accusing the company of creating a misleading impression about the indication for the rare disease drug. June 3, 2026 BioSpace - Business Facing pressure from China, BioSpace’s NextGen biotech leaders say: ‘Bring it on’ From Chinese innovation to AI, biotech CEOs are being hit with challenges at a breakneck pace. Three leaders from BioSpace’s NextGen Class of 2026 told us about the issues keeping... June 3, 2026 BioSpace - Business No longer a bargain pool, Chinese biotechs command higher premiums Deal dynamics between Chinese biotechs and global pharma companies are changing fast, with the biotechs seeking higher upfront payments and the Big Pharmas seeking more expansive platform deals. June 3, 2026 BioSpace - Deals No longer a bargain pool, Chinese biotechs command higher premiums Deal dynamics between Chinese biotechs and global pharma companies are changing fast, with the biotechs seeking higher upfront payments and the Big Pharmas seeking more expansive platform deals. June 3, 2026 BioSpace - Business Pharma manufacturing projected to create 19,000 jobs through 2034 The forecast makes pharma one of the fastest-growing manufacturing industries in the U.S. June 3, 2026 FierceBiotech - Main IMU Biosciences nabs $53M funding round to ‘decode’ the immune system British medtech startup IMU Biosciences has landed a £40 million ($53 million) series A as it looks to move immune system analysis from analog to “high definition.” June 3, 2026 FierceBiotech - Medtech IMU Biosciences nabs $53M funding round to ‘decode’ the immune system British medtech startup IMU Biosciences has landed a £40 million ($53 million) series A as it looks to move immune system analysis from analog to “high definition.” June 3, 2026 FiercePharma - Main Neurotech launches new YouTube channel to spotlight patients’ stories for rare eye disorder As Neurotech Pharmaceuticals looks to ramp up the launch of its first-ever commercial product, the biopharma is running a new video series to help boost awareness. June 3, 2026 FiercePharma - Marketing Neurotech launches new YouTube channel to spotlight patients’ stories for rare eye disorder As Neurotech Pharmaceuticals looks to ramp up the launch of its first-ever commercial product, the biopharma is running a new video series to help boost awareness. June 3, 2026 FiercePharma - Main As Akeso takes center stage at ASCO, China biotech industry cements its coming of age In 2017, a little-known company called Nanjing Legend Biotech walked into the ASCO annual meeting at the 11th hour, dropped a 100% objective response rate for a cell therapy that... June 2, 2026 FierceBiotech - Main As Akeso takes center stage at ASCO, China biotech industry cements its coming of age In 2017, a little-known company called Nanjing Legend Biotech walked into the ASCO annual meeting at the 11th hour, dropped a 100% objective response rate for a cell therapy that... June 2, 2026 BioPharma Dive Celcuity breast cancer drug misses ‘lofty’ expectations in ASCO-spotlighted trial Gedatolisib could “establish a new standard of care” for PIK3CA-mutated breast cancer, an investigator said, but the results nonetheless appeared to disappoint investors. June 2, 2026 BioPharma Dive Eli Lilly issues data sharing ultimatum to 340B hospitals Select hospitals have refused to share data to prove they’re not double-dipping drug discounts, Lilly said. Hospitals, which have until Monday to comply, are urging the government to intervene. June 2, 2026 FierceBiotech - Main Ascidian, Lilly ink RNA exon editing pact worth up to $1.9B for genetic kidney diseases Ascidian Therapeutics and Eli Lilly have signed a research collaboration potentially worth up to $1.9 billion, giving the Big Pharma company the chance to discover and develop RNA exon editing... June 2, 2026 FierceBiotech - Biotech Ascidian, Lilly ink RNA exon editing pact worth up to $1.9B for genetic kidney diseases Ascidian Therapeutics and Eli Lilly have signed a research collaboration potentially worth up to $1.9 billion, giving the Big Pharma company the chance to discover and develop RNA exon editing... June 2, 2026 BioSpace - Drug Development ASCO: Pfizer scores in lung, colorectal and prostate cancer but key readouts still to come Pfizer showcased multiple late-breakers at the American Society of Clinical Oncology’s annual conference but its biggest data are expected later this year. June 2, 2026 BioSpace - Drug Development ASCO: Merck overshadowed by upstart biotechs but TROP2 plans begin to pay off Merck may not have had the splashiest presentation at the American Society of Clinical Oncology meeting, but the data show why the Big Pharma remains king of oncology, analysts say. June 2, 2026 FiercePharma - Main Eli Lilly's ultimatum to hospitals: Send 340B claims data by June 8 or lose discounts The drugmaker has issued a June 8 ultimatum to an unspecified number of hospitals that have resisted a data submission policy it implemented in February. Furious hospital industry groups are... June 2, 2026 FiercePharma - Main Marilyn Monroe and Amy Schumer profiled in endometriosis awareness push A nonprofit has launched to change how endometriosis is researched, treated and understood, starting with a documentary that features the stories of people including, Amy Schumer and Marilyn Monroe. June 2, 2026 FiercePharma - Marketing Marilyn Monroe and Amy Schumer profiled in endometriosis awareness push A nonprofit has launched to change how endometriosis is researched, treated and understood, starting with a documentary that features the stories of people including, Amy Schumer and Marilyn Monroe. June 2, 2026 BioSpace - Deals Lilly bets $3B+ to add China’s Haisco to growing list of partners in five-program pact Eli Lilly and the Haisco Pharmaceutical Group have yet to disclose what specific indications they plan to prioritize. June 2, 2026 FiercePharma - Main Merck shrinks headcount by 88 in New Jersey as $3B cost-cutting scheme advances A Merck spokesperson attributed the layoffs to "the next phase of personnel impacts related to its multiyear optimization," which was unveiled last July. June 2, 2026 BioSpace - Deals Big Pharma makes ‘creative effort’ to fold Chinese assets into pipelines Recent deals from Pfizer and Bristol Myers Squibb hint at Big Pharma’s more collaborative approach to partnering with Chinese companies. June 2, 2026 FiercePharma - Main Gilead's Livdelzi scores in rare liver disease trial, portending use in broader patient population A phase 3 study of Gilead’s Livdelzi has met its primary endpoint, showing that after 52 weeks it can normalize a key marker of disease progression for those with the... June 2, 2026 FierceBiotech - Main Travere scales Everest with $1.1B deal for BTK inhibitor aimed at rare kidney diseases Travere Therapeutics has set its sights on Everest Medicines' therapy for rare kidney diseases, handing over $112.5 million upfront for a drug that has already begun the trek into the... June 2, 2026 FierceBiotech - Biotech Travere scales Everest with $1.1B deal for BTK inhibitor aimed at rare kidney diseases Travere Therapeutics has set its sights on Everest Medicines' therapy for rare kidney diseases, handing over $112.5 million upfront for a drug that has already begun the trek into the... June 2, 2026 FiercePharma - Main Sanofi taps Snowflake for AI field agent help French drugmaker Sanofi is launching an AI agent to support its field reps as life sciences companies continue to ramp up their use of next-generation technology across their businesses. June 2, 2026 FiercePharma - Marketing Sanofi taps Snowflake for AI field agent help French drugmaker Sanofi is launching an AI agent to support its field reps as life sciences companies continue to ramp up their use of next-generation technology across their businesses. June 2, 2026 FiercePharma - Main Merck weighs use of COVID antiviral Lagevrio as Ebola outbreak worsens As governments and health authorities rush to meet the moment of a worsening Ebola outbreak in central Africa, Merck & Co. is considering dusting off its antiviral molnupiravir, which saw... June 2, 2026 FiercePharma - Main ADHD drug delivery specialist Cingulate hit with manufacturing-related FDA rejection Cingulate will need to take a detour to win its first FDA approval, as the agency has rejected its lead candidate over manufacturing concerns. June 2, 2026 FiercePharma - Manufacturing ADHD drug delivery specialist Cingulate hit with manufacturing-related FDA rejection Cingulate will need to take a detour to win its first FDA approval, as the agency has rejected its lead candidate over manufacturing concerns. June 2, 2026 FierceBiotech - Main New heights for NewLimit as anti-aging biotech nabs $435M to rejuvenate old cells Anti-aging startup NewLimit is back with a fresh fundraise of $435 million after landing on its first clinic-ready candidate years earlier than expected. June 2, 2026 FierceBiotech - Biotech New heights for NewLimit as anti-aging biotech nabs $435M to rejuvenate old cells Anti-aging startup NewLimit is back with a fresh fundraise of $435 million after landing on its first clinic-ready candidate years earlier than expected. June 2, 2026 FierceBiotech - Main Fulcrum scraps SCD program, considers options after FDA takes hard line on safety risks Fulcrum Therapeutics has scrapped its sole clinical-stage program after the FDA took a hard line on the modality following the recent withdrawal of Ipsen’s Tazverik from the U.S. market. June 2, 2026 FierceBiotech - Biotech Fulcrum scraps SCD program, considers options after FDA takes hard line on safety risks Fulcrum Therapeutics has scrapped its sole clinical-stage program after the FDA took a hard line on the modality following the recent withdrawal of Ipsen’s Tazverik from the U.S. market. June 2, 2026 FierceBiotech - Main Foundation Medicine tallies FDA nod to pair its blood test with Pfizer’s prostate cancer combo Foundation Medicine tallied another nod from the FDA for one of its genomic profiling tests that searches for specific biomarkers in tumor tissue samples. June 2, 2026 FierceBiotech - Medtech Foundation Medicine tallies FDA nod to pair its blood test with Pfizer’s prostate cancer combo Foundation Medicine tallied another nod from the FDA for one of its genomic profiling tests that searches for specific biomarkers in tumor tissue samples. June 2, 2026 FiercePharma - Marketing Eisai whips up Alzheimer’s dietary guidance to expand nutrition program beyond cancer Eisai has partnered with CaringKind to expand its nutrition support initiative to cover Alzheimer's disease and related dementias. June 2, 2026 FierceBiotech - Biotech Praxis pauses one of its seizure programs after phase 2 fail Praxis Precision Medicines’ epilepsy pipeline has suffered a setback after a next-gen NaV blocker failed to sufficiently reduce seizures in a phase 2/3 study. June 2, 2026 FierceBiotech - Biotech Abivax stock suffers as cancer cases overshadow stellar efficacy in ulcerative colitis phase 3 trial Abivax has raised the efficacy bar in ulcerative colitis, linking obefazimod to a 40%, placebo-adjusted jump in clinical remission rates in a phase 3 trial. But the share price of... June 2, 2026 FierceBiotech - Main ASCO: Cardiff posts updated colorectal cancer data ahead of pivotal push Cardiff Oncology has shared updated results from its phase 2 colorectal cancer trial, revealing that the study drug has yet to reach the median progression-free survival as the biotech prepares... June 2, 2026 FierceBiotech - Biotech ASCO: Cardiff posts updated colorectal cancer data ahead of pivotal push Cardiff Oncology has shared updated results from its phase 2 colorectal cancer trial, revealing that the study drug has yet to reach the median progression-free survival as the biotech prepares... June 2, 2026 FierceBiotech - Main MindMaze Therapeutics culls program, ends legacy ops from Relief merger to cut costs Digital therapeutics specialist MindMaze Therapeutics is selling off a pipeline program while also removing all non-neurology legacy operations from its recent merger with Relief Therapeutics. June 2, 2026 FierceBiotech - Medtech MindMaze Therapeutics culls program, ends legacy ops from Relief merger to cut costs Digital therapeutics specialist MindMaze Therapeutics is selling off a pipeline program while also removing all non-neurology legacy operations from its recent merger with Relief Therapeutics. June 2, 2026 FierceBiotech - Biotech ASCO: Takeda touts ‘tremendous potential’ of Innovent’s PD-1/IL-2 bispecific after seeing survival data Takeda and Innovent's long-term follow-up data from an early study of their collaborative PD-1/IL-2 bispecific colors the "tremendous potential" of the asset, Takeda's P.K. Morrow said in an interview. June 1, 2026 FierceBiotech - Biotech ASCO: Celcuity dares to dream of becoming $10B company after breast cancer win over Piqray While Revolution Medicines dominated this year’s American Society of Clinical Oncology annual meeting by conquering the “undruggable” RAS pathway, another up-and-coming biotech hopes to do the same with a different... June 1, 2026 FierceBiotech - Biotech Mesutoclax points to possible shift in high-risk MDS and AML Early ASCO 2026 data show strong responses and improved safety with mesutoclax in high-risk MDS and AML. Hear what it may mean for treatment. June 1, 2026 FierceBiotech - Biotech At ASCO 2026, a ‘paradigm shift’ for a rare gut cancer looms For patients with a rare cancer that arises in the gut wall, standard treatment hasn’t changed in the last 20 years. At the American Society of Clinical Oncology meeting in... June 1, 2026 FierceBiotech - Biotech ASCO: Bristol Myers’ $800M bispecific ADC aces China breast cancer study, putting TROP2 drugs on notice The first-in-class EGFRxHER3 bispecific ADC that BMS paid $800 million for has shown strong phase 3 results from China that suggest it could put up a fight against blockbuster TROP2... June 1, 2026 FierceBiotech - CRO ASCO, Ryght AI team up for breast cancer trial site selection The American Society of Clinical Oncology (ASCO) and Ryght AI are teaming up to identify research sites for an ASCO clinical trial evaluating starting doses of CDK4/6 inhibitors in patients... June 1, 2026 FiercePharma - Marketing ViiV Healthcare launches ‘PrEP Wisdom’ campaign to boost awareness of long-acting HIV prevention meds ViiV Healthcare is teaming up with TV personality, HIV and LGBTQ advocate Michelle Visage to help broaden awareness about new, longer-acting medicines that can significantly reduce the risk of HIV... June 1, 2026 FiercePharma - Marketing Rising Stars: WPP’s Meghan O’Hora on the ‘complex puzzle’ of oncology drug marketing For Meghan O’Hora, pharma marketing isn’t about patients. It’s about people and making real connections that help them see beyond their diagnosis toward a healthier future. June 1, 2026 BioSpace - FDA Cracked gaskets and rust-like residues trigger FDA warning letter to Alchymars FDA inspectors found Alchymars failed to adequately maintain equipment used to make active pharmaceutical ingredients for the U.S. market. Over-the-counter drugmakers GC America and Sato Pharmaceutical also received warning letters. May 29, 2026 BioSpace - Drug Delivery Cracked gaskets and rust-like residues trigger FDA warning letter to Alchymars FDA inspectors found Alchymars failed to adequately maintain equipment used to make active pharmaceutical ingredients for the U.S. market. Over-the-counter drugmakers GC America and Sato Pharmaceutical also received warning letters. May 29, 2026 BioSpace - FDA Replimune gives cancer immunotherapy a third try after FDA leadership shakeup Replimune’s resubmission for RP1 for melanoma comes amid the departures of FDA leaders in place at the time of the drug’s first two rejections, last summer and again in April. May 29, 2026 BioSpace - FDA FDA delays verdict on Beren’s rare disease drug by three months Beren Therapeutics is seeking approval in Neimann-Pick disease type C, an application the FDA was set to decide on by August 17. The new target action date is November 17. May 29, 2026 FiercePharma - Marketing Pharma urged to modernize patient support as young adult cancer rates rise Pharma companies need to strengthen and modernize patient support programs to reflect rising rates of cancer in adults aged 18 to 49 years, an Omnicom Health report found. May 29, 2026 FiercePharma - Marketing Philips adds a spoonful of Disney sugar to ease kids’ MRI anxieties Philips has integrated animated Disney characters and stories into MRI machines to make imaging scans more comforting and engaging for children. May 29, 2026 BioSpace - FDA AbbVie snags FDA's first ADC approval for ultra-rare blood cancer Decnupaz is the first antibody-drug conjugate for blastic plasmacytoid dendritic cell neoplasm, an ultra-rare and aggressive blood cancer. May 28, 2026 FierceBiotech - CRO Icon ends internal accounting investigation, finds it overstated revenue in prior years Irish CRO Icon has concluded its investigation into its accounting practices and restated its consolidated financials for 2023 and 2024. May 28, 2026 FiercePharma - Marketing PharmaEssentia taps Incyte alum Eric Vogel as it eyes Besremi expansion PharmaEssentia has hired Eric Vogel as its new U.S. Head of Commercialization as it seeks to broaden the label of its rare blood cancer drug Besremi to a much wider... May 28, 2026 FiercePharma - Marketing Kaléo speaks up on allergy awareness to amplify patient stories Kaléo has launched the “AUVI-Q Speaks Up” campaign to share patients’, caregivers’ and healthcare providers’ stories about life with severe allergies. May 28, 2026 FierceBiotech - Medtech Human Longevity launches newco, teams with Insilico for AI-powered longevity research Human Longevity, which is seeking to use biology and genomics to boost the human lifespan, has launched a new company called Human Life Foundation Models (HLFM) to help with its... May 28, 2026 BioSpace - FDA FDA accepts BridgeBio’s application for potential first limb-girdle muscular dystrophy drug The FDA’s priority review acceptance of BridgeBio’s BBP-418 is another step toward what William Blair previously dubbed a “diversified commercial portfolio.” It also adds to the rapidly building momentum in... May 27, 2026 FiercePharma - Manufacturing Viridian, awaiting FDA decision, taps WuXi Bio in eye drug supply deal Viridian aims to challenge Amgen in a blockbuster market, and it's now tapped Chinese CDMO giant WuXi Biologics in a manufacturing pact. May 27, 2026 BioSpace - FDA Lilly just bought renowned regulator Peter Marks a pipeline to play with FDA veteran Peter Marks will now shape the future of Eli Lilly’s vaccines work after the buys of Curevo, LimmaTech Biologics and Vaccine Company for up to $3.8 billion total. May 27, 2026 BioSpace - FDA FDA assembles vaccine experts to update COVID-19 formulation The FDA will convene its vaccines advisory panel to discuss seasonal COVID-19 vaccines—a surprise move after Health Secretary and vaccine skeptic Robert F. Kennedy, Jr. overhauled a separate vaccine committee. May 27, 2026 FierceBiotech - CRO Kordata Dynamics launches with neural-focused AI clinical trial model Kordata Dynamics is emerging from stealth with the aim to redefine clinical trial execution by processing neural data while taking advantage of the FDA’s recent push for real-time clinical trials. May 27, 2026 FiercePharma - Manufacturing GLP-1 manufacturer CordenPharma strikes deal for peptide CDMO, lining up new production sites in US and China Amid a nearly $1 billion GLP-1 manufacturing expansion that began in 2024, CMDO CordenPharma is doubling down on its peptide capacity ambitions. May 27, 2026 FierceBiotech - Medtech Dexcom warns of stolen glucose monitors being sold by unauthorized dealers Dexcom warned that some lots of its G7 wearable glucose monitors were stolen on their way to the scrapyard and were sold by a third-party vendor. May 27, 2026 FiercePharma - Marketing Biogen investigated by Italian regulator over multiple sclerosis ‘market abuse’ claims Italy’s antitrust agency, the Italian Competition Authority (AGCM), is investigating Biogen and its Italian subsidiary over claims it is abusing its market position regarding a test for its multiple sclerosis... May 27, 2026 FierceBiotech - Medtech Insulet issues voluntary correction for Omnipod devices in leaky insulin fault Insulet has sent out a voluntary medical device correction notice for a series of its Omnipod devices amid a manufacturing fault that could lead to insulin leaking and not being... May 27, 2026 FiercePharma - Marketing Eli Lilly wins argument over Noom’s GLP-1 dosing claims Eli Lilly has successfully challenged Noom’s “A Smaller Dose. A Smarter Start” claim, leading the National Advertising Division (NAD) to recommend the digital health company change or drop the statement. May 27, 2026 FiercePharma - Manufacturing SK bioscience links up with Colombia to enable local production of varicella vaccine Korea’s SK bioscience has signed a technology transfer and manufacturing deal with the Colombian government which will allow the South American nation to produce the company’s chickenpox vaccine SKYVaricella. May 26, 2026 FiercePharma - Marketing Acadia boosts ‘More To Parkinson's’ campaign with Ryan Reynolds, Parkinson’s voices Two years after launching its “More To Parkinson’s” campaign with actor Ryan Reynolds, Acadia Pharmaceuticals is asking Reynolds to suit up once again as it broadens the project. May 26, 2026 FiercePharma - Manufacturing Niowave kicks off construction of $75M radiopharmaceutical isotope plant in Michigan Niowave has broken ground on a $75 million facility at its campus in Lansing, Michigan, which will produce Actinium-225. The radioisotope supplier expects the facility to become operational in 2028... May 25, 2026 BioSpace - Drug Delivery Gilead inks $140M API supply deal, tightening ties to Korean manufacturer The agreement is the largest in a series of deals that Gilead Sciences has penned with Korea’s Yuhan. May 22, 2026 FiercePharma - Marketing AbbVie, GSK race up patient reputation leaderboard in the UK AbbVie and GSK have surged up the rankings of the pharma companies with the best reputations among U.K. patient groups, contributing to turnover at the top of the leaderboards. May 22, 2026 FiercePharma - Marketing Tyra creates awareness day with patient advocates to shine light on a rare cancer Tyra Biosciences has partnered with a patient advocacy group to create an awareness day for upper tract urothelial cancer, a rare tumor type its lead drug candidate targets. May 22, 2026 FiercePharma - Marketing Inside agency view: Ogilvy Health on AI’s ‘light speed,’ nano influencers and the rise of Ria Healthcare agencies remain at the forefront of pharmaceutical marketing, but new technologies and shifting political dynamics are putting increasing pressure on the industry. May 21, 2026 BioSpace - Drug Delivery Lilly and Engage Bio tie the knot with $202M acquisition Eli Lilly joins hands with Engage Bio, acquiring the DNA delivery platform developer in hopes of bolstering its genetic medicines portfolio. May 20, 2026 FierceBiotech - Medtech Medtronic inks $650M deal for SPR Therapeutics Medtronic has entered a deal to acquire SPR Therapeutics, a Cleveland-based company whose flagship product delivers short-term electrical nerve stimulation for chronic pain patients, for approximately $650 million in cash. May 20, 2026 FiercePharma - Marketing Ipsen details growing pains as teens transition to adult care An Ipsen-commissioned survey has identified widespread problems with the transition from pediatric to adult healthcare, prompting the drugmaker to call for more resources to help people manage the shift. May 20, 2026 FierceBiotech - Medtech Qiagen links with chip giant Nvidia to propel AI use in drug discovery Qiagen, a Netherlands-based diagnostics maker, is linking with tech giant Nvidia in a collaboration aimed at boosting the ability of researchers to leverage AI in the drug discovery process. May 20, 2026 FiercePharma - Manufacturing Gilead inks another deal with Korean API manufacturer Yuhan, this time worth $140M Gilead has broadened its partnership with Korean manufacturer Yuhan, agreeing to a $140 million supply deal for active pharmaceutical ingredients for an undisclosed product. May 20, 2026 FierceBiotech - Medtech Labcorp joins lab results personalization push with ‘MyLabcorp’ AI app The big new thing in medtech for 2026 is AI-powered apps and chatbots designed to help patients navigate their laboratory test results. Now, testing giant Labcorp is getting in on... May 20, 2026 FierceBiotech - Medtech Endologix acquires thrombectomy system from Surmodics Endologix, a medtech that focuses on treatments for vascular diseases, expanded its offerings with the purchase of a mechanical thrombectomy system from Surmodics. May 20, 2026 FierceBiotech - Medtech Herantis taps Indivi for digital biomarker tech in Parkinson’s disease trial Finnish biotech Herantis Pharma is teaming up with Swiss medtech Indivi to help seek early detection of Parkinson’s disease in a new proof-of-concept clinical trial. May 19, 2026 BioSpace - Drug Delivery Deep dive: The oral obesity wars BioSpace examines how the FDA approval of Eli Lilly’s oral obesity drug Foundayo has ignited a key race with Novo Nordisk. May 18, 2026 FiercePharma - Manufacturing Novartis terminates plant contract with Chinese CDMO Porton, threatens $64M in legal claims A Novartis cross-border partnership is turning into a standoff. The Swiss pharma has unilaterally terminated a plant leasing contract with Chinese CDMO Porton Pharma Solutions after a regulatory hiccup. May 18, 2026 FierceBiotech - CRO Clinical trial flaws ‘being scaled, not solved’ by AI: report Clinical trial data company Phesi’s new analysis found that fewer than one in three trial protocols are connected to documented patient data and outcomes, highlighting the risk that flawed decision-making... May 18, 2026 FiercePharma - Manufacturing Bristol Myers looks at Houston for potential $1B manufacturing plant As Bristol Myers looks for suitable sites for a large U.S. manufacturing plant, Houston has emerged as one contender. May 18, 2026 FierceBiotech - Medtech Boston Scientific funnels $1.5B into MiRus, with option to buy TAVR system Acquisitive Boston Scientific is making deals again, with a major investment play into a private medtech with an option to snap up exclusive rights to its Transcatheter Aortic Valve Replacement... May 18, 2026 FierceBiotech - Medtech Lauxera Capital Partners raises a hefty €520M for health, medtech companies Lauxera Capital Partners has nearly doubled the size of its first funding drive with a €520 million ($605 million) raise for health and medical technology companies. May 18, 2026 FierceBiotech - Medtech Ardent Health taps Fujifilm’s AI-enabled patient imaging platform Fujifilm Healthcare Americas Corp. has signed a deal with Ardent Health to bring its enterprise imaging software to hospitals and clinics in six states. May 18, 2026 FiercePharma - Manufacturing As biologics dominate biopharma pipelines, manufacturing hurdles trip up new launches: report As biologics have increasingly superseded small molecules in the biopharma industry’s pipeline, the mounting complexity of their manufacturing products is putting production and launches under pressure. May 15, 2026 FierceBiotech - Medtech NeuroVision acquires fellow dx player Durin Life Sciences NeuroVision, which is working toward regulatory approval for its early Alzheimer’s detection technology, acquired fellow diagnostics maker Durin Life Sciences for an undisclosed price. May 15, 2026 FierceBiotech - CRO Signant Health buys Ametris to unite data streams in clinical trials Tech provider Signant Health announced the acquisition of Ametris to unite its electronic clinical outcome assessments with Ametris’ wearable-derived digital outcome measures. May 14, 2026 FiercePharma - Manufacturing Sun recalls US chemotherapy batch, citing glass particle contamination concerns Generics juggernaut Sun Pharma is pulling one lot of a chemotherapy drug in the United States as the issue of particulate contamination crops up once again on the FDA’s recall... May 14, 2026 FiercePharma - Manufacturing Bora snaps up MacroGenics’ manufacturing, CDMO operations for up to $127.5M Taiwan’s Bora Group will shell out up to $127.5 million to acquire the CDMO business and manufacturing operations from Maryland-based MacroGenics. May 14, 2026 FierceBiotech - CRO Icon opens early-phase research unit in San Antonio, plus satellite clinics to grow trial capabilities Global contract research organization Icon has announced the opening of a new research facility in San Antonio, Texas, along with satellite clinics in Houston and Lawrence, Kansas, to expand its... May 13, 2026 FierceBiotech - Medtech Humacyte cuts spending, staff as it seeks to boost sluggish sales for its off-the-shelf artery implant Humacyte was riding high in December 2024 when it secured an FDA green light for a groundbreaking implant. Now, as it looks to boost sales of the device, it’s making... May 13, 2026 FierceBiotech - Medtech Medtronic to shutter Santa Rosa plant as it restructures cardiovascular unit Medtronic will shutter its Santa Rosa facility that produces coronary stents and other heart-related products over the next two years as the device maker also looks to restructure its cardio... May 13, 2026 FierceBiotech - Medtech AstraZeneca pens agentic AI licensing deal with Owkin AstraZeneca is the latest Big Pharma company looking to tap into agentic artificial intelligence (AI), inking a three-year licensing deal with Owkin to leverage its autonomous “AI Scientist” platform. May 13, 2026 FiercePharma - Manufacturing EU advances scheme to bolster manufacturing autonomy, avert drug shortages After positive momentum on the plan in late 2025, European Union lawmakers have taken a critical step toward implementing a new framework for the bloc focused on boosting supplies of... May 12, 2026 FierceBiotech - Medtech Charles River debuts AI diagnostic tool to cut down pathology timelines Charles River is rolling out an artificial intelligence-backed digital pathology platform with a goal of trimming at least one week from standard pathology timelines and workflows. May 12, 2026 FierceBiotech - Medtech Roche nabs European approval for second Eli Lilly-partnered Alzheimer’s test Roche has secured a European CE mark for its second Alzheimer’s test that can both help confirm the disease and rule it out. May 12, 2026 FierceBiotech - CRO Banyan BioInnovations puts down roots with $100M, Icon partnership Banyan BioInnovations is debuting with more than $100 million aimed at developing NewCos around promising clinical assets, plus a partnership with global contract research organization Icon. May 7, 2026 FiercePharma - Manufacturing FDA rolls out 1-day assessment pilot in bid to refocus inspection resources In a bid to better deploy its boots-on-the-ground resources, the FDA is rolling out a new pilot program, under which the regulator is leveraging “one-day inspectional assessments” to complement its... May 6, 2026 BioSpace - Policy Unforced errors flummox HHS’ radical transparency bid—again Robert F. Kennedy Jr.’s health department has consistently touted radical transparency as being key to its mission. Recent instances—the FDA’s decision not to disclose the recipients of three Commissioner’s National... May 6, 2026 FierceBiotech - CRO Bipartisan PRIMATE Act aims to ban monkey imports to US A new bipartisan bill could end the import of primates for U.S. research, targeting the roughly 20,000 monkeys brought into the country each year for laboratories or their suppliers. May 6, 2026 FiercePharma - Manufacturing The timing is right for psychedelics manufacturer Optimi Health's IPO Last month, when Optimi Health kicked off an initial public offering of 2.5 million shares, the timing couldn’t have been better for the Vancouver-based manufacturer of psychedelic drugs. With President Donald... May 6, 2026 FiercePharma - Manufacturing Lilly to invest $4.5B more into massive Indiana manufacturing complex With commitments to invest more than $50 billion in building up its U.S. manufacturing presence, Eli Lilly has earmarked an additional $4.5 billion to upgrade two of its three planned... May 6, 2026 FiercePharma - Manufacturing Novartis to close German manufacturing site, cutting 220 jobs Novartis is continuing its multiyear overhaul with new plans to shutter its production facility in Wehr, Germany, by 2028. The move, announced Tuesday, will eliminate about 220 jobs, according to... May 5, 2026 FiercePharma - Manufacturing BioNTech to slash 1,860 jobs, exit sites in Germany and Singapore in major manufacturing pullback The German vaccine maker plans to wind down operations at a handful of its sites in Germany plus one in Singapore, putting as many as 1,860 jobs on the chopping... May 5, 2026 FiercePharma - Manufacturing Prolific Machines sets monoclonal antibody manufacturing record with light-controlled platform Though largely operating in the background until recently, Prolific Machines’ optogenetic approach to biomanufacturing is set to make waves thanks to the achievement of an impressive milestone in monoclonal antibody... May 4, 2026 FiercePharma - Manufacturing CDMO Samsung Biologics estimates $102M impact stemming from ongoing union strike The company chalks up a financial impact of about 150 billion Korean won ($102 million) from "preemptive production adjustments" made to mitigate potential manufacturing impacts, a spokesperson said. May 4, 2026 FierceBiotech - CRO WCG acquires The Contract Network in bid to streamline clinical trial execution Clinical trials solutions provider WCG is acquiring tech company The Contract Network to improve alignment and decision-making across clinical trial initiation. April 24, 2026 BioSpace - Policy Regeneron finally joins Trump’s drug pricing push while notching landmark approval Of the 17 companies that were implored by the White House last July to apply Most Favored Nation pricing to their drugs, Regeneron is the last to agree—the same day... April 24, 2026 BioSpace - Policy Unnamed pharma files citizen petition targeting FDA’s trove of rejection letters The FDA in July 2025 made publicly available over 200 complete response letters—an initiative that the investment community sees as “unanimously positive,” analysts told BioSpace. April 23, 2026 BioSpace - Drug Delivery AbbVie commits $1.4B to NC plant in its largest-ever single campus investment The Durham plant will manufacture immunology, neuroscience and oncology drugs once AbbVie finishes construction in 2028. April 23, 2026 BioSpace - Drug Delivery The next era of diabetes management In this episode of Denatured, you'll be hearing from Dr. Sarah Howell, CEO at Arecor Therapeutics and Dr. Wendy S. Lane, clinical endocrinologist and diabetologist. We examine how increasingly connected... April 23, 2026 BioSpace - Policy Lilly, Novo dip as proposed Medicare coverage for GLP-1 pilot thrown off balance Two of the biggest insurance providers have expressed reluctance to participate in the government’s BALANCE program that would have made GLP-1 drugs more affordable to patients. April 22, 2026 BioSpace - Policy Trump throws support behind psychedelics with executive order A new executive order could usher in psychedelics as the “key next wave” of mental health therapies, according to analysts at RBC Capital Markets. April 20, 2026 FierceBiotech - CRO FDA celebrates progress to end animal testing but experts warn there’s still a long way to go The FDA says it has hit the one-year goals of its roadmap for ending animal testing. Experts are split on how impactful the agency's actions will be. April 19, 2026 BioSpace - Policy RFK Jr. defends Makary, claims pharma ‘owns’ Congress and media The pharma industry “own Congress, they own the media,” Health Secretary Robert F. Kennedy, Jr. told lawmakers by way of explaining the bad press against FDA Commissioner Marty Makary following... April 17, 2026 BioSpace - Drug Delivery Funding the future of European biotech In this episode of Denatured, you'll be hearing from Edoardo Negroni, co-founder & managing partner at AurorA-TT and Naveed Siddiqi, senior partner, Venture Investments at Novo Holdings. We debate whether... April 16, 2026 BioSpace - Policy Trump nominates new CDC director, appoints various leaders to embattled agency Erica Schwartz, a former deputy surgeon general and member of the U.S. military, will take over from what has amounted to a rapid succession of CDC leaders over the past... April 16, 2026 BioSpace - Policy Drug pricing watchdog calls for increased transparency into FDA’s accelerated approval decisions Greater transparency in FDA decision-making was possibly the most common theme for stakeholders interviewed by the Institute for Clinical and Economic Review in a new report focused on strengthening the... April 16, 2026 BioSpace - Drug Delivery FDA mulls compounding for peptides previously flagged over safety risks With Health Secretary Robert F. Kennedy Jr. declaring himself “a big fan of peptides,” the FDA has arranged an advisory committee to discuss allowing compounders to make molecules despite earlier... April 16, 2026 FierceBiotech - CRO RyghtAI launches clinical site search engine to aid drug developers, CROs with trial design Clinical site selection platform RyghtAI has launched a search engine designed to give drug developers and contract research organizations access to a comprehensive database of clinical research sites. April 16, 2026 BioSpace - Policy Deep dive: Checking in with the FDA BioSpace looks back at 2025 and where the FDA is going in 2026. April 15, 2026 FierceBiotech - CRO Rare Disease Research, myTomorrows team up to help patients access trials Clinical trial site network Rare Disease Research (RDR) is partnering with health tech company myTomorrows to increase trial visibility and support more referrals from community and specialist care settings for... April 14, 2026 BioSpace - Drug Delivery Your Scale, Your Terms: How Modular Bioreactors Are Redefining Capacity & Manufacturing Strategies Principal Scientist Anders Cai Holm Hansen explains how CDMO AGC Biologics uses its global, single-use network and a strategy emphasizing “scale-out” manufacturing, to derisk demand uncertainty, speed timelines and conserve... April 13, 2026 FierceBiotech - CRO Akari locks arms with WuXi XDC to develop and manufacture novel ADC treatment Oncology biotech Akari Therapeutics has announced a partnership with WuXi XDC, an antibody-drug conjugate (ADC) development and manufacturing company, to accelerate Akari’s drug development and manufacturing. April 8, 2026 FierceBiotech - CRO CRO Fortrea launches AI-powered solution to improve trial efficiency Fortrea is expanding its capabilities with a suite of AI-powered technologies designed to automate workflows, streamline oversight and improve productivity for trial sponsors. April 7, 2026 FierceBiotech - CRO Thousands of clinical trial sites impacted by Middle East conflict: report Nearly 8,000 clinical trial sites have been affected by the joint strikes on Iran by the U.S. and Israel and Iran’s subsequent retaliation, according to a report from clinical data... April 1, 2026 FierceBiotech - CRO BMS links up with Faro to use AI to improve clinical trial protocols Bristol Myers Squibb has tapped up Faro to use AI to improve the Big Pharma's clinical trial protocols. March 30, 2026 FierceBiotech - CRO Icon, Advarra partnership aims to optimize trials, expand access Clinical research organization Icon has entered into a partnership with research technology company Advarra to launch a network of connected sites for clinical trials. March 24, 2026 FierceBiotech - CRO Syneos Health scoops up Chinese CRO to secure place in 'rapidly growing market' North Carolina-based contract research organization Syneos Health is making a play to capitalize on China’s rapidly ascendant biopharma industry. Syneos has acquired Chinese CRO Bestudy to secure a foothold in... March 19, 2026 FierceBiotech - CRO Agilent to acquire Biocare in $950M 'complementary combination' Bay Area laboratory solutions company Agilent Technologies has agreed to acquire Biocare Medical, an antibody, reagent and instrument business, in an all-cash transaction valued at $950 million. March 11, 2026 FierceBiotech - CRO UK invests $64M to expand clinical trial access to underserved communities In an effort to boost global biopharma competitiveness, the U.K.’s National Institute for Health and Care Research (NIHR) has awarded £47.8 million ($64 million) to 51 National Health Service (NHS)... March 4, 2026 FiercePharma - Vaccines South Africa's Biovac produces first Pfizer COVID-19 vaccine doses: report More than a year after partnering with Pfizer to boost COVID-19 vaccine supply in Africa, South Africa's Biovac has produced its first batch of shots, Bloomberg reports. The development follows... September 14, 2022 FiercePharma - Vaccines After 'watershed' approval, Takeda nears dengue vaccine launch and gears up for more green lights It's been a long journey for Takeda's dengue fever vaccine, which recently won its first global approval in Indonesia. After Sanofi's dengue vaccine disaster, the company had to learn from... August 31, 2022 FiercePharma - Vaccines Takeda's dengue fever vaccine picks up first global nod in Indonesia After a long road, Takeda's dengue fever vaccine has finally picked up its first global approval in Indonesia, where the dengue fever epidemic runs rampant. The approval was based on... August 22, 2022 FiercePharma - Vaccines Bavarian Nordic secures another deal with undisclosed European country for 1.5M Jynneos doses As countries scramble to ensure a stockpile of smallpox and monkeypox vaccine Jynneos, Bavarian Nordic signed yet another deal to an undisclosed European country for 1.5 million doses. July 19, 2022 FiercePharma - Vaccines Bavarian Nordic inks deal to supply U.S. with 2.5M more Jynneos doses As monkeypox continues to spread worldwide, the U.S. has ordered another 2.5 million doses of Bavarian Nordic's vaccine, Jynneos. July 18, 2022 FiercePharma - Vaccines Merck's Hilleman Laboratories tees up $58M investment at new Singapore vaccine hub Singapore has attracted a slate of pharma heavyweights in recent years. Now, a Merck and Welcome Trust joint venture is throwing its hat in the ring. December 6, 2021 FiercePharma - Vaccines Sanofi aims to double vaccine sales by 2030, citing RSV and flu market expansion as key drivers While Sanofi hasn’t been at the forefront of global COVID-19 vaccination efforts, the company still has big growth expectations in the vaccines field. Already the world’s top flu shot player, Sanofi sees mRNA,... December 1, 2021 FiercePharma - Vaccines Pfizer's next-gen Prevnar 20 can be administered with a flu shot, study finds As Pfizer gears up for its next big vaccine launch in Prevnar 20, the company is touting positive top-line results for a co-administration trial with a seasonal flu shot. The... September 29, 2021 FiercePharma - Vaccines Merck will pay royalties on next-gen pneumococcal shot to settle Pfizer patent fight Even before Merck and Pfizer won back-to-back FDA nods for their rival pneumococcal conjugate vaccines this summer, the companies were fighting it out in courts over patents on the lucrative... September 24, 2021 FiercePharma - Vaccines GSK, Pfizer and Johnson & Johnson race toward $10B-plus RSV vaccine market: analyst While COVID-19 vaccines set all sorts of industry launch records, another potential megablockbuster vaccine market looms on the horizon. Some of pharma's top players, including Pfizer, Johnson & Johnson and GlaxoSmithKline... September 8, 2021 FiercePharma - Vaccines As GlaxoSmithKline works to get Shingrix back on track, an FDA approval increases the key vaccine's reach The coronavirus pandemic nudged GlaxoSmithKline's rising star Shingrix off course. But the shingles vaccine is primed for a rebound, especially with a new indication, for adults who are immunocompromised. July 26, 2021 FiercePharma - Vaccines FDA slaps Guillain-Barré warning on GlaxoSmithKline's star vaccine Shingrix GlaxoSmithKline’s vaccine cash cow Shingrix has a new safety warning on its label after the FDA found an increased risk for the rare neuro autoimmune disorder Guillain-Barré Syndrome in a... March 25, 2021 FiercePharma - Vaccines Novavax was on its last leg pre-COVID. With a promising shot on deck, it's now eyeing a big 2021 Heading into last year, Novavax had just $80 million in cash and a “financial operating horizon” of six months, its CEO said this week. That's all changed. Nowadays, the biotech... March 3, 2021 FiercePharma - Vaccines Ready to square off with Pfizer in next-gen pneumococcal vaccines, a Merck exec says competition's a good thing As next-gen pneumococcal vaccines from Merck & Co. and Pfizer work through the FDA review process—and as an important CDC committee weighs data this week—a Merck exec says he embraces the competition that's likely... February 25, 2021 FiercePharma - Vaccines Amid supply snafu, new data show AstraZeneca's COVID-19 shot is more effective with doses 12 weeks apart While supply constraints have hung over the rollout of the AstraZeneca COVID-19 vaccine in Europe, last week, the company's CEO Pascal Soriot offered one way that officials could make the most out... February 2, 2021 FiercePharma - Vaccines GSK, Clover part ways on COVID-19 vaccine, putting Dynavax in the spotlight First, lackluster data forced GlaxoSmithKline and partner Sanofi back to the drawing board with their COVID-19 shot. Now, the Big Pharma and a biotech partner are parting ways on a... February 1, 2021 FiercePharma - Vaccines Novavax sees some COVID-19 vaccine trial dropout as Pfizer, Moderna rollouts gear up As supplies of Pfizer-BioNTech and Moderna’s authorized COVID-19 vaccines make their way around the country, many states are expanding beyond the 75-plus age group to reach people 10 years younger.... January 20, 2021 FiercePharma - Vaccines mRNA latecomer CureVac recruits Bayer to speed COVID-19 vaccine to market Compared with Moderna and the Pfizer-BioNTech partnership, which already have their COVID-19 vaccines authorized for emergency use, CureVac seems a little late to the mRNA race. But now, Bayer has... January 7, 2021 FiercePharma - Vaccines Pfizer's 'Prevnar 20' gets in FDA fast lane as next-gen pneumococcal vaccine race heats up with Merck Pfizer and Merck are both laboring away on COVID-19 vaccines, but neither has lost sight of their multibillion-dollar race for next-gen pneumococcal shots. And now, Pfizer has scored a regulatory... December 9, 2020 FiercePharma - Vaccines Pfizer, BioNTech nab COVID-19 vaccine authorization from U.K. for first-ever marketed mRNA shot Pfizer and BioNTech have made history. The two companies’ BNT162b2 has become the first COVID-19 vaccine allowed in the Western world as drug regulators in the U.K. doled out an... December 2, 2020 Load More
